Black Diamond Therapeutics, Inc. 8-K

What Happened
Black Diamond Therapeutics, Inc. announced the final results of its virtual 2026 Annual Meeting of Stockholders held June 26, 2026 (record date April 28, 2026). A quorum was present with 44,690,495 shares represented of 57,301,774 shares outstanding. Stockholders elected two Class III directors, ratified PricewaterhouseCoopers LLP (PwC) as the company’s independent auditor for 2026, approved a non‑binding advisory vote on executive compensation, and voted to hold future advisory votes on executive compensation annually.

Key Details

• Shares outstanding (record date April 28, 2026): 57,301,774; shares represented at the meeting: 44,690,495.
• Director elections (Class III): Shannon Campbell elected — For 19,251,021; Withheld 17,219,135; Broker non‑votes 8,220,339. Kapil Dhingra elected — For 13,966,232; Withheld 22,503,924; Broker non‑votes 8,220,339.
• Auditor ratification (Proposal No. 2): PwC ratified — For 44,421,545; Against 117,976; Abstain 150,974.
• Executive compensation advisory (Proposal No. 3): Approved — For 35,071,684; Against 1,243,945; Abstain 154,527; Broker non‑votes 8,220,339.
• Frequency vote (Proposal No. 4): Stockholders chose annual votes — 1‑year: 30,446,520; 2‑year: 84,537; 3‑year: 5,740,812; Abstain 198,287; Broker non‑votes 8,220,339.

Why It Matters
These outcomes confirm the company’s board composition (two Class III directors seated) and retention of PwC as auditor, both important to corporate governance. The advisory approval of executive compensation and the decision to hold future advisory votes annually mean shareholders will have a yearly opportunity to express their views on executive pay. Investors can use these results to assess shareholder support for management and governance practices.